Literature DB >> 2384304

Phase II trial of sequential methotrexate and 5-fluorouracil with leucovorin in children with sarcomas.

F M Balis1, A Gillespie, J Belasco, G H Reaman, L J Ettinger, R F Murphy, K Doherty, S Jeffries, M E Horowitz, D G Poplack.   

Abstract

Entities:  

Mesh：

Substances：

Year:  1990        PMID： 2384304     DOI： 10.1007/bf00177254

Source DB:  PubMed          Journal:  Invest New Drugs        ISSN： 0167-6997            Impact factor:   3.850


× No keyword cloud information.
  9 in total

1.  Use of 5-fluorouracil in the management of advanced maligancies in childhood.

Authors:  W KRIVIT; H P BENTLEY
Journal:  Am J Dis Child       Date:  1960-08

2.  Enzymatic assay for methotrexate in serum and cerebrospinal fluid.

Authors:  L C Falk; D R Clark; S M Kalman; T F Long
Journal:  Clin Chem       Date:  1976-06       Impact factor: 8.327

3.  Effectiveness of intermediate-dose methotrexate and high-dose 5-fluorouracil as sequential combination chemotherapy in refractory breast cancer and as primary therapy in metastatic adenocarcinoma of the colon.

Authors:  G Tisman; S J Wu
Journal:  Cancer Treat Rep       Date:  1980 Aug-Sep

4.  Sequential infusions of methotrexate and 5-fluorouracil in advanced cancer: pharmacology, toxicity, and response.

Authors:  C Benz; M DeGregorio; S Saks; N Sambol; W Holleran; R Ignoffo; B Lewis; E Cadman
Journal:  Cancer Res       Date:  1985-07       Impact factor: 12.701

5.  Methotrexate and 5-fluorouracil in head and neck cancer.

Authors:  U Ringborg; G Ewert; J Kinnman; P G Lundquist; H Strander
Journal:  Semin Oncol       Date:  1983-06       Impact factor: 4.929

6.  Schedule-dependent cytotoxicity of methotrexate and 5-fluorouracil in human colon and breast tumor cell lines.

Authors:  C Benz; M Schoenberg; M Choti; E Cadman
Journal:  J Clin Invest       Date:  1980-11       Impact factor: 14.808

7.  Sequential methotrexate and 5-fluorouracil in the primary treatment of metastatic colorectal carcinoma.

Authors:  J A Ajani; M D Kanojia; A Y Bedikian; J K Korinek; S H Stein; E G Espinoza; G P Bodey
Journal:  Am J Clin Oncol       Date:  1985-02       Impact factor: 2.339

8.  Stability of 5-fluorouracil in whole blood and plasma.

Authors:  R F Murphy; F M Balis; D G Poplack
Journal:  Clin Chem       Date:  1987-12       Impact factor: 8.327

9.  Methotrexate as relapse therapy for rhabdomyosarcoma.

Authors:  U Bode
Journal:  Am J Pediatr Hematol Oncol       Date:  1986
  9 in total
  1 in total

1.  Translational Pharmacokinetic-Pharmacodynamic Modeling and Simulation: Optimizing 5-Fluorouracil Dosing in Children With Pediatric Ependymoma.

Authors:  V M Daryani; Y T Patel; M Tagen; D C Turner; A M Carcaboso; J M Atkinson; A Gajjar; R J Gilbertson; K D Wright; C F Stewart
Journal:  CPT Pharmacometrics Syst Pharmacol       Date:  2016-04-14
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.